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Ralph Brinster to Receive Gairdner
Foundation International Award 
Dr. Ralph L. Brinster,V’60, the Richard King Mellon
Professor of Reproductive Physiology, will be awarded the
Gairdner Foundation International Award on October 26,
2006 in Toronto. Dr. Brinster is receiving the award for his
“pioneering discoveries in germ line modification in
mammals.”
First awarded in 1959, the Gairdners are among the
most prestigious international awards in medical research,
recognizing outstanding
contributions by medical
scientists whose work will
significantly improve the
quality of life.Among the 279
Gairdner winners during the
past 46 years, 65 have gone on
to win the Nobel Prize.
Dr. Brinster’s research career
is noted for many achievements
in the field of reproduction,
genetics and stem cell biology.
In particular, Brinster has been
a leader in the biology of germ
cells. Early in his career, he established techniques to grow
and manipulate eggs, and later used these methods to
generate genetic changes in mice and other animals. More
recently, Dr. Brinster has created a technique of altering
genes in spermatagonial stem cells.
“Ralph Brinster is truly a trailblazer in the field of gene
modification in animals,” said Dr. Joan Hendricks,
V’79, GR’80, dean of the School.“His early findings
helped usher in the era of transgenic research and its many
medical and scientific benefits, while his current work is at
the forefront of stem cell medicine.”
Dr. Brinster is the sixth Penn faculty member—and the
first from the School of Veterinary Medicine—to win a
Gairdner, a list that includes Clay Armstrong (2001),
Baruch S. Blumberg (1975), Britton Chance (1972),
Daniel J. McCarty (1965) and John H. Gibbon (1960), all
from the School of Medicine.
“Bubble Bassets” Cured of 
Genetic Disorder
Researchers from Penn Vet have found a way to cure
basset hound puppies of a deadly immune disorder, a
victory that could eventually change the way the disease is
treated in humans.
The disease, X-linked severe combined immunodefi-
ciency, or XSCID, first received public attention with
“Bubble Boy” David Vetter, a victim who could survive
only in an isolated, germ-free environment.Today, the dis-
ease affects one in every 100,000 boys and often proves
fatal before the age of one year.
Although XSCID has been treated in the past through
a gene therapy technique in which bone marrow is taken
out of a patient, treated with the corrective gene, then
placed back in the body, the Vet School team used a
different approach, injecting the corrective gene directly
into the bloodstream of the pups.
“Although ex-vivo gene therapy has been shown to be
capable of restoring normal immune function in XSCID
boys, there are several potential problems with this
approach,” said Dr. Peter J. Felsburg,V’69, professor of
immunology, who led the team that included researchers
from the National Institute of Allergy and Infectious
Disease.“The number of gene-corrected bone-marrow
stem cells that can be transplanted back into the patient is
limited to correcting the potentially low number of bone-
marrow stem cells harvested from the patient. In addition,
the manipulation and culturing of the cells outside the
body may alter their ability to provide for long-term
generation of new immune cells.”
This procedure, the team says, could prove to be both a
more effective and more efficient treatment of the disease
in years to come.
By Air—and Water
A recent discovery of five fossils in northwestern China
provides an important link between ancient and modern
birds.The fossils indicate that early birds probably evolved
16 BELLWETHER FALL 2006
Effective this issue, Rosettes & Ribbons, which highlights faculty and staff accomplishments, is
now being offered on-line.We are very excited by this new format, which allows us enhanced
content flexibility, more up-to-date listings and a wider reach. Be sure to check it out at
www.vet.upenn.edu/bellwether/rosettes.shtml!
ro s e t t e s & r i b b o n s  
has moved on-line!
in a watery
environment and
were similar to
modern-day ducks
or loons.The bone
structure and
webbed feet of the
specimens—called
Gansus yumenensis for the province in which they were
found—indicate that they swam and took flight from the
water.Though no skulls were found, it seems likely that
that these duck-like early birds ate fish, insects and the
occasional plant.
“Gansus is very close to a modern bird and helps fill in
the big gap between clearly non-modern birds and the
explosion of early birds that marked the Cretaceous
period, the final era of the Dinosaur Age,” said Dr. Peter
Dodson, professor of anatomy, who discovered the fossils
with three former students.
A Jekyll-and-Hyde of Cytokines:
IL-25 Promotes and Limits
Inflammatory Diseases 
The same signal responsible for promoting the type of
immune responses that cause asthma and allergy can also
limit the type of inflammation associated with debilitating
diseases like inflammatory bowel disease, arthritis and
multiple sclerosis, according to Penn Vet researchers.The
team discovered how IL-25, a signaling protein known as
a cytokine, prevents destructive
inflammation and promotes
immune responses associated
with asthma and allergic
responses.
The findings, which appear in
the April 2006 Journal of
Experimental Medicine, suggest
that manipulating IL-25 could provide a method to treat a
wide variety of chronic inflammatory diseases.
“It appears that IL-25 has a Jekyll-and-Hyde
personality: it can be helpful or hurtful depending on how
it interacts with T helper cells, a subset of immune cells
that influences inflammatory responses,” said Dr. David
Artis, assistant professor of parasitology and senior author
of the study.“These studies show that IL-25 promotes
type-2 T helper cells that drive the type of response
required for eradicating worm infections and causing
asthma. Importantly, IL-25 can simultaneously limit
destructive inflammation caused by inflammatory T helper
cells commonly found in diseases like inflammatory bowel
disease, arthritis and MS.”
These results also support the notion that the immune
response that causes allergies and asthma is an evolutionary
hangover resulting from mankind’s historical fight with
parasitic worm infections.That is, a type-2 response once
useful in fighting worm infections has now become a
dangerous menace, causing inflammatory responses to
commonly encountered environmental antigens.About 30
percent of Americans suffer from the negative effects of
type-2 inflammation: asthma and allergies, which result
from an inflammatory response to factors encountered in
the environment, whether industrial air pollutants or
peanut-oil molecules.
Funding was provided by the National Institutes of
Health, the Crohns and Colitis Foundation of America’s
William Shelby Modell Family Foundation Research
Award, the Irvington Institute for Immunological
Research Postdoctoral Fellowship and Schering-Plough
Biopharma.
New Treatment at Ryan Veterinary
Hospital for Feline Saddle Thrombus
In July 2006, the Matthew J. Ryan Veterinary Hospital
Emergency Service, in tandem with Ryan’s Interventional
Radiology Service, began offering rheolytic
thrombectomy for the treatment of certain blood clots
encountered in veterinary patients.The AngioJet
Thrombectomy Device historically has been used to
remove blood clots in humans. Recently, rheolytic
thrombectomy was described for the treatment of feline
distal aortic thromboembolism, with encouraging initial
results.This procedure involves placement of a specialized
catheter through the carotid artery and into the saddle
thrombus using fluoroscopic guidance. Once in place,
the thrombus is fragmented and evacuated, restoring
perfusion to the limbs.
Saddle thrombi secondary to heart disease in our
feline patients is a frustrating disease historically
associated with extreme patient discomfort and a
grave prognosis.The researchers’ current study
will focus on aggressive, rapid removal of these
thrombi as soon as possible with concurrent
management of the underlying cardiac disease
and anticipated reperfusion injury to maximize
outcome in these patients.These techniques can
be used in dogs with certain thromboembolic
manifestations as well.
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Reconstruction of the Early Cretaceous amphibious
bird Gansus yumenensis, in a lake in China. Gansus
demonstrates that the ancestors of today’s birds
may have been semiaquatic in habit. llustration by
Mark A. Klingler/CMNH.
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Researchers Find Role for
MicroRNAs in Oxygenation,
Nourishing of Colon Tumors 
Researchers at Penn Vet have identified how molecules of
microRNA are responsible for the growth of blood vessels
in a model for human colon cancer. The process, called
angiogenesis, results in the ability of ravenous cancer cells
to recruit blood vessels and receive a steady supply of
nutrients and oxygen.
The findings, which appear in the on-line version of
Nature Genetics, suggest these microRNAs might also be a
good target for future therapeutics to slow the growth of
cancer cells.
“These findings also uncover a new role for a well-
known cancer-causing gene called MYC,” said Dr.Andrei
Thomas-Tikhonenko, associate professor of pathobiology.
“We have discovered that, within a tumor cell, one of the
tasks of MYC is to turn loose a particular set of
microRNAs, which then becomes responsible for promoting
the growth of new blood vessels that nourish the tumor.”
The researchers discovered the role of microRNAs in
angiogenesis while studying what makes MYC unique
among other cancer-causing genes. In particular, they were
curious why cells with hyperactive MYC do not accumu-
late particularly fast in Petri dishes yet grow explosively in
animal models for the disease.
The MYC protein is known to have a role in deter-
mining how certain genes are transcribed into messenger
RNAs.To understand the role of MYC in angiogenesis,
the researchers used microarray technology to screen
MYC-positive and -negative cancerous cells for the pres-
ence or absence of 192 known pro- and anti-angiogenesis
molecules.They found that, while MYC did not lead to
excessive amounts of pro-angiogenesis molecules, it did
seem to depopulate an entire family of anti-angiogenesis
molecules related to the thrombospondin-1 protein. MYC
effectively disabled the brakes that slow angiogenesis.
Also participating in this study were Asal
Homayouni, Duonan Yu and Cinzia Sevignani from
the School of Veterinary Medicine; Greg H. Enders,
Emma E. Furth,William M. Lee and Danielle Murphy
from Penn’s School of Medicine; and Erik Wentzel from
Johns Hopkins University. Funding for this research was
provided by the National Institutes of Health and a grant
from the University of Pennsylvania Research Foundation.
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